Vera Therapeutics, Inc.(VERA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VERA Vera Therapeutics, Inc.

交易中 02-09 10:31:54 EST

42.83

-0.67

-1.54%

最高43.44	最低42.21	成交量8.01万
今开43.25	昨收43.50	日振幅2.83%
总市值30.01亿	流通市值21.50亿	总股本7,007万
成交额342.80万	换手率0.16%	流通股本5,020万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":42.83,"timestamp":1770651113177,"preClose":43.5,"halted":0,"volume":80051,"delay":0,"changeRate":-0.015402298850574751,"floatShares":50198200,"shares":70066174,"eps":-3.99905,"marketStatus":"交易中","change":-0.67,"latestTime":"02-09 10:31:54 EST","open":43.245,"high":43.44,"low":42.21,"amount":3428018.36943,"amplitude":0.028276,"askPrice":42.92,"askSize":22,"bidPrice":42.71,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.99905,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":43.5,"preHourTrading":{"tag":"盘前","latestPrice":43.49,"preClose":43.5,"latestTime":"09:29 EST","volume":11277,"amount":489563.179749,"timestamp":1770647399999,"change":-0.01,"changeRate":-0.00023,"amplitude":0.036092},"postHourTrading":{"tag":"盘后","latestPrice":43.05,"preClose":43.5,"latestTime":"19:50 EST","volume":61751,"amount":2685990.92,"timestamp":1770425456025,"change":-0.45,"changeRate":-0.010345,"amplitude":0.010345},"volumeRatio":0.493342,"impliedVol":1.135,"impliedVolPercentile":0.745},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2601936805","title":"Vera Therapeutics的肾病药物获美国FDA优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936805","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601936805?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:26","pubTimestamp":1767792390,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4539","VERA","LENZ","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1144135600","title":"Vera Therapeutics肾病药物获FDA优先审评 盘前股价飙升14.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144135600","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144135600?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:49","pubTimestamp":1767790156,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc. (VERA) 股价在盘前交易中大幅上涨14.4%，此前该公司宣布其用于治疗肾脏疾病的药物已获得美国食品药品监督管理局（FDA）的优先审评资格。\n这一利好消息显著提振了投资者信心，反映出市场对该药物获批前景的乐观预期。FDA的优先审评通常旨在加速针对严重疾病且可能提供显著治疗优势的药物的审评流程。\n此次审评资格的获得，标志着Vera Therapeutics在肾病治疗领域的研发进展迈出了关键一步，也为公司未来的商业化前景注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","VERA","BK4585","BK4139"],"gpt_icon":0},{"id":"1156747929","title":"Vera Therapeutics获美国FDA优先审评Atacicept治疗成人IgA肾病生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1156747929","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156747929?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:30","pubTimestamp":1767789033,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc.宣布，其针对成人免疫球蛋白A肾病（IgA肾病）治疗的生物制剂Atacicept，已获得美国食品药品监督管理局（FDA）授予的生物制剂许可申请（BLA）优先审评资格。\n此次优先审评将显著缩短FDA的审评周期，意味着该创新疗法有望更快惠及患者。IgA肾病作为一种进展性自身免疫性肾病，目前临床治疗选择有限，Atacicept的研发进展备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4139","BK4585","BK4588","BK4539"],"gpt_icon":0},{"id":"1144679814","title":"富国银行：美股“轧空行情”即将来临，这些股票或将迎来交易机会","url":"https://stock-news.laohu8.com/highlight/detail?id=1144679814","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144679814?lang=zh_cn&edition=full","pubTime":"2026-01-07 10:34","pubTimestamp":1767753273,"startTime":"0","endTime":"0","summary":"富国银行预计多重利好因素将推动美国股市上涨，尤其是那些被大量做空但表现滞后的股票。在周二发布的研究报告中，富国银行分析师Ohsung Kwon及其团队从罗素3000指数中筛选出一批被大量做空且表现落后、但有望即将反弹的股票。去年10月，美国银行在首次覆盖报告中给予Vera\"买入\"评级，目标价48美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c76459198a96f48579b9be57b060ec45","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c76459198a96f48579b9be57b060ec45"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IR","MNKD","MTDR","VERA","CRGY","ENOV","HRI","HASI"],"gpt_icon":1},{"id":"1184126239","title":"Vera Therapeutics第三季度每股收益为-1.26美元，低于IBES预期的-1.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184126239","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184126239?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:42","pubTimestamp":1763570545,"startTime":"0","endTime":"0","summary":"11月5日 - Vera Therapeutics第三季度运营亏损为8393.2万美元，而IBES预期为7730万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","VERA","BK4588","BK4585"],"gpt_icon":0},{"id":"1185157267","title":"异动解读 | Vera Therapeutics盘后大涨6.24%，公司向FDA提交重要药物申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1185157267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185157267?lang=zh_cn&edition=full","pubTime":"2025-11-08 07:54","pubTimestamp":1762559660,"startTime":"0","endTime":"0","summary":"生物制药公司Vera Therapeutics在周五收盘后股价大涨6.24%，引起投资者广泛关注。这一显著涨幅与公司最新发布的重要进展密切相关。据报道，Vera Therapeutics向美国食品和药物管理局 提交了其重要产品Atacicept的生物制剂许可证申请。该申请旨在通过加速审批程序，寻求Atacicept用于治疗成人IgA肾病的批准。IgA肾病是一种严重的肾脏疾病，目前治疗选择有限，因此Atacicept的潜在批准可能为患者带来新的希望。这一申请标志着Vera Therapeutics在其药物开发进程中迈出了关键一步。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VERA"],"gpt_icon":0},{"id":"1157171725","title":"Vera Therapeutics向美国FDA提交了Atacicept的生物制剂许可证申请，旨在通过加速审批程序治疗成人IgA肾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1157171725","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157171725?lang=zh_cn&edition=full","pubTime":"2025-11-08 07:28","pubTimestamp":1762558096,"startTime":"0","endTime":"0","summary":"Vera Therapeutics向美国FDA提交了Atacicept的生物制剂许可证申请，旨在通过加速审批程序治疗成人IgA肾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VERA","BK4139","BK4585","BK4539"],"gpt_icon":0},{"id":"1184925377","title":"Vera Therapeutics公布了在2025年ASN肾脏周会上发布的Atacicept在IgA肾病中的积极ORIGIN III期数据，并在《新英格兰医学杂志》上发表","url":"https://stock-news.laohu8.com/highlight/detail?id=1184925377","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184925377?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:52","pubTimestamp":1762440735,"startTime":"0","endTime":"0","summary":"Vera Therapeutics公布了在2025年ASN肾脏周会上发布的Atacicept在IgA肾病中的积极ORIGIN III期数据，并在《新英格兰医学杂志》上发表","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4539","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1150782398","title":"Vera Therapeutics将于2025年11月6日东部时间下午4:30召开投资者电话会议及网络广播，更新Origin 3进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1150782398","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150782398?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:03","pubTimestamp":1761134629,"startTime":"0","endTime":"0","summary":"Vera Therapeutics将于2025年11月6日东部时间下午4:30召开投资者电话会议及网络广播，更新Origin 3进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","BK4588","BK4139","VERA"],"gpt_icon":0},{"id":"1137213965","title":"Vera Therapeutics宣布Origin 3最新摘要入选2025年ASN肾脏周开幕全体会议的特色口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1137213965","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137213965?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:13","pubTimestamp":1760706794,"startTime":"0","endTime":"0","summary":"Vera Therapeutics宣布Origin 3最新摘要入选2025年ASN肾脏周开幕全体会议的特色口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4139","BK4585","BK4588","BK4539"],"gpt_icon":0},{"id":"2518207880","title":"Vera Therapeutics, Inc.盘中异动 下午盘股价大跌5.10%报27.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518207880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518207880?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:02","pubTimestamp":1741633362,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时02分，Vera Therapeutics, Inc.股票出现异动，股价大幅下跌5.10%。截至发稿，该股报27.35美元/股，成交量34.9152万股，换手率0.55%，振幅5.69%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6185.95%、3855.31%、1016.34%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031103024298a2dc61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031103024298a2dc61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","VERA","BK4539","LENZ"],"gpt_icon":0},{"id":"2517592133","title":"Vera Therapeutics, Inc.盘中异动 股价大涨5.28%报30.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517592133","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517592133?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:53","pubTimestamp":1741208002,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时53分，Vera Therapeutics, Inc.股票出现波动，股价快速拉升5.28%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.87%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Chimerix, Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为990.11%、322.79%、321.36%，振幅较大的相关个股有Nkgen Biotech Inc C/Wts 31/05/2028、Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为497.01%、82.59%、54.27%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045323abea1c37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045323abea1c37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","BK4139","BK4539","VERA","BK4588"],"gpt_icon":0},{"id":"2516663454","title":"Vera Therapeutics, Inc.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663454","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663454?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:44","pubTimestamp":1741034655,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时44分，Vera Therapeutics, Inc.股票出现波动，股价大幅跳水5.08%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4654.37%、216.36%、188.06%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044416a25da762&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044416a25da762&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VERA","LENZ","BK4588","BK4539","BK4139","BK4585"],"gpt_icon":0},{"id":"2514382851","title":"Vera Therapeutics, Inc.盘中异动 早盘股价大涨5.08%报29.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514382851?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:02","pubTimestamp":1740672133,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时02分，Vera Therapeutics, Inc.股票出现异动，股价急速拉升5.08%。截至发稿，该股报29.18美元/股，成交量9.7414万股，换手率0.15%，振幅3.29%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Pepgen Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1480.34%、246.33%、109.54%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000213abdf8540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000213abdf8540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4139","BK4585","BK4539","VERA"],"gpt_icon":0},{"id":"2514856036","title":"Vera Therapeutics, Inc.盘中异动 快速拉升5.06%报28.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856036","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856036?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580337,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Vera Therapeutics, Inc.股票出现波动，股价大幅拉升5.06%。截至发稿，该股报28.47美元/股，成交量1.2618万股，换手率0.02%，振幅2.10%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2818.09%、118.03%、90.31%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为35.59%、16.86%、14.35%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223217a254f69f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223217a254f69f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VERA","BK4539","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1153119985","title":"Vera Therapeutics 2024 财年 GAAP 每股收益 $(2.75) 超过 $(2.83) 预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153119985","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153119985?lang=zh_cn&edition=full","pubTime":"2025-02-26 21:38","pubTimestamp":1740577116,"startTime":"0","endTime":"0","summary":"Vera Therapeutics报告季度每股亏损为 $，这比分析师一致预估的 $ 高出2.83%。与去年同期每股亏损 $ 相比，这一数字下降了22.22%。以上内容来自Benzinga Earnings专栏，原文如下：Vera $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.83 percent. This is a 22.22 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VERA"],"gpt_icon":0},{"id":"2512166077","title":"Vera Therapeutics, Inc.盘中异动 急速拉升6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166077","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166077?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889129,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，Vera Therapeutics, Inc.股票出现异动，股价大幅拉升6.34%。截至发稿，该股报29.20美元/股，成交量3.05万股，换手率0.05%，振幅3.53%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为276.09%、91.01%、60.62%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Allakos Inc.、Virpax Pharmaceuticals, Inc.，振幅分别为8.57%、8.35%、6.13%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182232099889fca3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182232099889fca3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","BK4139","BK4539","VERA","BK4588"],"gpt_icon":0},{"id":"2511993146","title":"Vera Therapeutics, Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511993146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511993146?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:50","pubTimestamp":1739544622,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时50分，Vera Therapeutics, Inc.股票出现波动，股价大幅下跌5.03%。截至发稿，该股报32.46美元/股，成交量5.2783万股，换手率0.08%，振幅5.56%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1914.86%、497.45%、427.85%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为66.93%、32.93%、32.49%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422502398858e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422502398858e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","VERA","BK4588","BK4585","BK4539"],"gpt_icon":0},{"id":"2510338776","title":"Vera Therapeutics, Inc.盘中异动 股价大跌5.13%报34.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338776","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338776?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:07","pubTimestamp":1739286435,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时07分，Vera Therapeutics, Inc.股票出现异动，股价大幅下跌5.13%。截至发稿，该股报34.04美元/股，成交量4.6683万股，换手率0.07%，振幅3.83%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.52%。其相关个股中，Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2505.47%、744.73%、330.29%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为52.11%、39.80%、37.99%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230715961f4eaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230715961f4eaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VERA","BK4539","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2507420621","title":"Vera Therapeutics, Inc.盘中异动 大幅上涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507420621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507420621?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:35","pubTimestamp":1738247713,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时35分，Vera Therapeutics, Inc.股票出现波动，股价快速上涨5.30%。截至发稿，该股报39.94美元/股，成交量2.1831万股，换手率0.03%，振幅3.27%。Vera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Alterity Therapeutics Limited、Tectonic Therapeutic, Inc.、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为721.86%、129.52%、109.80%，振幅较大的相关个股有Kazia Therapeutics Limited、Tectonic Therapeutic, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为28.25%、24.49%、21.31%。Vera Therapeutics, Inc.公司简介：Vera Therapeutics Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022351496143e15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022351496143e15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4539","LENZ","VERA","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.1064},{"period":"3month","weight":0.7983},{"period":"6month","weight":1.1981},{"period":"1year","weight":0.17},{"period":"ytd","weight":-0.141}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vera Therapeutics, Inc.最初于2016年5月在特拉华州注册成立，名称为CDF Therapeutics，Inc.，并于2020年4月更名为Vera Therapeutics, Inc.。该公司是一家处于临床后期阶段的生物技术公司，专注于为患有严重免疫疾病的患者开发和商业化转化疗法。该公司的主要候选产品atacicept是一种自我给药的融合蛋白，可阻断B淋巴细胞刺激物和增殖诱导配体，具有治疗IgA肾病的同类最佳潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.6,"avgChangeRate":0.028368},{"month":3,"riseRate":0.5,"avgChangeRate":-0.056274},{"month":4,"riseRate":0,"avgChangeRate":-0.100599},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Vera Therapeutics, Inc.(VERA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Vera Therapeutics, Inc.(VERA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}